Department of Neonatology, Sri Ramachandra Institute of Higher Education & Research, Chennai 600116, India.
J Trop Pediatr. 2022 Dec 5;69(1). doi: 10.1093/tropej/fmac110.
Postnatal growth failure happens in about half of the very low birth weight infants and this can have long-term consequences. Human milk-based multi-nutrient fortifiers (HMBF) are thought to be better tolerated than bovine milk-based multi-nutrient fortifiers (BMBF), thus facilitating early progression to full feeds and improved growth in preterm neonates. This study was done to find the advantage of HMBF over BMBF on postnatal growth and other clinical outcomes.
This is a retrospective cohort study where babies <1500 g birth weight or gestational age <32 weeks were included to compare the velocity of weight gain (g/kg/day), duration of hospital stay and clinical outcomes between fortification using HMBF and BMBF till 34 weeks postmenstrual age.
Eligible neonates included in the study were 322, out of whom 123 (37%) received HMBF and 209 (63%) received BMBF. During the stay, 18 babies were changed from BMBF to HMBF and vice versa in 24 babies due to logistic reasons and parents' preferences. The mean birth weight of the babies was 1124 ± 237 g. Weight gain was higher in the exclusive HMBF group [mean difference 0.77 (0.14, 1.39) g/kg/day; p-value = 0.018]. Feed intolerance [odds ratio (OR) 0.45 (0.22, 0.95), p-value 0.037] was also significantly less in this group. However, other morbidities did not differ significantly between the groups.
Higher weight gain and lower feed intolerance in the HMBF group underscores the possible advantage of using HMBF over BMBF. Larger prospective studies might bring out its effect on the duration of hospital stay and other morbidities.
约一半极低出生体重儿存在生后生长不良,这可能会带来长期影响。人们认为,基于人乳的多营养强化剂(HMBF)比基于牛乳的多营养强化剂(BMBF)更易耐受,因此能促进早产儿尽早过渡到全营养配方奶,并改善其生长情况。本研究旨在评估 HMBF 相较于 BMBF 对生后生长及其他临床结局的优势。
本研究为回顾性队列研究,纳入出生体重<1500g 或胎龄<32 周的患儿,比较强化治疗使用 HMBF 和 BMBF 至校正胎龄 34 周时的体重增长速度(g/kg/天)、住院时间及临床结局。
本研究共纳入 322 例符合条件的新生儿,其中 123 例(37%)接受 HMBF,209 例(63%)接受 BMBF。在住院期间,18 例患儿因客观因素和家长偏好将 BMBF 更换为 HMBF,24 例患儿将 HMBF 更换为 BMBF。患儿平均出生体重为 1124±237g。HMBF 组患儿体重增长更高[平均差异 0.77(0.14,1.39)g/kg/天;p 值=0.018],喂养不耐受率也显著更低[比值比(OR)0.45(0.22,0.95),p 值=0.037]。但两组患儿的其他并发症无显著差异。
HMBF 组患儿体重增长更高、喂养不耐受率更低,提示 HMBF 可能优于 BMBF。更大规模的前瞻性研究可能会进一步揭示 HMBF 对住院时间及其他并发症的影响。